Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: A clinical, endocrinological, metabolic pilot study

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 6, 2004, Pages 2817-2823

  Guido, M ^a   Romualdi, D ^a   Giuliani, M ^a   Suriano, R ^a   Selvaggi, L ^a   Apa, R ^a   Lanzone, A ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CHOLESTEROL; DROSPIRENONE; ESTROGEN DERIVATIVE; ETHINYLESTRADIOL; FAT; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HORMONE; HYDROXYPROGESTERONE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; PRASTERONE; PROGESTERONE DERIVATIVE; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ANDROGEN BLOOD LEVEL; BLOOD PRESSURE; BODY FAT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLAMP; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERABILITY; ECHOGRAPHY; ENDOCRINOLOGY; EVALUATION; FEMALE; HIRSUTISM; HOMEOSTASIS; HORMONE DETERMINATION; HUMAN; HYPERINSULINEMIA; LIPID ANALYSIS; LUTEINIZING HORMONE BLOOD LEVEL; METABOLISM; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PELVIS; PILOT STUDY; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; BLOOD PRESSURE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HIRSUTISM; HUMANS; MIDDLE AGED; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME; TRIGLYCERIDES;

FALLOPIA;

EID: 2942631366     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031158     Document Type: Conference Paper

References (43)

1. Franks S 1995 Polycystic ovary syndrome. N Engl J Med 333:853-861
2. Golland IM, Elstein ME 1993 Results of an open one-year study with Diane 35 in women with polycystic ovary syndrome. Ann NY Acad Sci 687:263-271
3. Falsetti L, Galbignani E 1990 Long term treatment with the combination ethinyl-estradiol and cyproterone acetate in polycystic ovary syndrome. Contraception 42:611-619
4. Shulman LP 2002 Safety and efficacy of a new oral contraceptive containing drospirenone. J Reprod Med 47(Suppl 11):981-984
5. Thorneycroft IH 2002 Evolution of progestins. Focus on the novel progestin drospirenone. J Reprod Med 47(Suppl 11):975-980
6. Shultz W 1996 Hormonal contraception, 2nd Ed. Berlin: Schering
7. Adams J, Polson DW, Abdulwahid N 1985 Multifollicular ovaries: clinical and endocrine features and response to gonadotropin releasing hormone. Lancet 2:1375-1378
8. Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V, Lanzone A 2001 A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril 76:326-331
9. Van Hooff MH, Voorhorst FJ, Koptein MB, Hirasing RA, Koppenaal C, Schoemaker J 1999 Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 years old adolescents. Hum Reprod 14:2223-2229
10. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy DJ, Pang S, Levine LS 1983 Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 57:320-326
11. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, Caruso A Lanzone A 1999 Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 48:167-172
12. De Simone M, Verrotti A, Iughetti L, Palombo M, Farello G, Di Cesare E, Bernabei R, Rosato T, Lozzi S, Ciescione S 2001 Increased visceral adipose tissue is associated with increased circulating insulin and decreased sex hormone binding globulin levels in massively obese adolescent girls. J Endocrinol Invest 24:438-444
13. Ferriman D, Gallwey JD 1961 Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440-1447
14. De Fronzo JP, Tobin JD, Andrei R 1979 Glucose clamp Technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
15. Bergman RN, Finegood DT, Ader M 1985 Assessment of insulin sensitivity in vivo. Endocr Rev 6:45-86
16. Fotherby K, Caldwell AD 1994 New progestogens in oral contraception. Contraception 49:1-32
17. Darney PD 1995 The androgenicity of progestins. Am J Med 98(Suppl 1A): 104s-110s
18. Cerel-Suhl SL, Yeager BF 1999 Update on oral contraceptive pills. Am J Obstet Gynecol 179:577-582
19. Krattenmacher R 2000 Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62:29-38
20. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH 1996 The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54:243-251
21. Givens JR, Andersen RN, Wiser WL, Fish SA 1974 Dynamic of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive. J Clin Endocrinol Metab 38:727-735
22. Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E 1995 Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity: pharmacological characterization in animal models. Contraception 51:99-110
23. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E 1995 Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 761:311-335
24. McCartney, Eagleson CA, Marshall JC 2002 Regulation of gonadotropin secretion: implications for polycystic ovary syndrome. Semin Reprod Med 20: 317-326
25. Adashi EY, Resnick CE, D'Ercole J, Svoboda ME, Van Wyk JJ 1985 Insulin-like growth factor as intraovarian regulators of granulosa cell growth and function. Endocr Rev 6:400-420
26. Falsetti L, Gambera A, Tisi G 2001 Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum Reprod 16:36-42
27. Chapman MG, Jeffcoate SL, Dewhurst CJ 1982 Effect of cyproterone acetate-ethinyl oestradiol treatment on adrenal function in hirsute women. Clin Endocrinol (Oxf) 17:577-582
28. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R 2002 The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 69(Suppl 4):2-15
29. Fotherby K, Caldwell AD 1994 New progestogens in oral contraception. Contraception 49:1-32
30. Heuser I, Deuschle M, Weber B, Stalla GK, Holsboer F 2000 Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology 25:513-518
31. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H 1998 The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J Clin Endocrinol Metab 83:3339-3345
32. Oelkers WK 1996 Effects of estrgens and progestgens on the renin-aldosterone system and blood pressure. Steroids 61:166-171
33. Oelkers W, Berger V, Bolik A, Bahr V, Hazard B, Beier S, Elger W, Heithecker A 1991 Dihydrospirenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 73:837-842
34. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R 1995 Effects of new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80:1816-1821
35. Parsey KS, Pong A 2000 An open-label, multicenter study to evaluate Yasmn, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 61:105-111
36. Skouby SO 1991 Oral contraceptives and changes in glucose metabolism: clinical relevance? Adv Contraception 7(Suppl 3):207-212
37. Spellacy WN 1982 Carbohydrate metabolism during treatment with estrgen, progestogen and low-dose oral contraceptives. Am J Obstet Gynecol 142:732-734
38. Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn 1990 The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323:1375-1381
39. WHO 1997 Acute myocardial infarction and combined oral contraceptives: results of international multicenter case-control study: WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 349:1202-1209
40. Wild RA 2002 Long-term health consequences of PCOS. Hum Reprod Update 8:231-241
41. Gaspard UJ 1991 Clinical relevance of plasma lipid changes during use of new low-dose oral contraceptives. Adv Contraception 7(Suppl 1):180-194
42. Castelli WP 1998 The new pathophysiology of coronary artery disease. Am J Cardiol 82:60t-65t
43. Sclavo M 2001 Cardiovascular risk factors and prevention in women: similarities and differences. Ital Heart J 2(Suppl 2):125-141